Literature DB >> 20129564

Culprit vessel percutaneous coronary intervention versus multivessel and staged percutaneous coronary intervention for ST-segment elevation myocardial infarction patients with multivessel disease.

Edward L Hannan1, Zaza Samadashvili, Gary Walford, David R Holmes, Alice K Jacobs, Nicholas J Stamato, Ferdinand J Venditti, Samin Sharma, Spencer B King.   

Abstract

OBJECTIVES: The purpose of this study was to examine the differences in in-hospital and longer-term mortality for ST-segment elevation myocardial infarction (STEMI) patients with multivessel disease as a function of whether they underwent single-vessel (culprit vessel) percutaneous coronary interventions (PCIs) or multivessel PCI.
BACKGROUND: The optimal treatment of patients with STEMI and multivessel disease is of continuing interest in the era of drug-eluting stents.
METHODS: STEMI patients with multivessel disease undergoing PCIs in New York between January 1, 2003, and June 30, 2006, were subdivided into those who underwent culprit vessel PCI and those who underwent multivessel PCI during the index procedure, during the index admission, or staged within 60 days of the index admission. Patients were propensity-matched and mortality rates were calculated at 12, 24, and 42 months.
RESULTS: A total of 3,521 patients (87.5%) underwent culprit vessel PCI during the index procedure. A total of 259 of them underwent staged PCI during the index admission and 538 patients underwent staged PCI within 60 days of the index procedure. For patients without hemodynamic compromise, culprit vessel PCI during the index procedure was associated with lower in-hospital mortality than multivessel PCI during the index procedure (0.9% vs. 2.4%, p = 0.04). Patients undergoing staged multivessel PCI within 60 days after the index procedure had a significantly lower 12-month mortality rate than patients undergoing culprit vessel PCI only (1.3% vs. 3.3%, p = 0.04).
CONCLUSIONS: Our findings support the American College of Cardiology/American Heart Association (ACC/AHA) recommendation that culprit vessel PCI be used for STEMI patients with multivessel disease at the time of the index PCI when patients are not hemodynamically compromised. However, staged PCI within 60 days after the index procedure, including during the index admission, is associated with risk-adjusted mortality rates that are comparable with the rate for culprit vessel PCI alone. Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20129564     DOI: 10.1016/j.jcin.2009.10.017

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  62 in total

Review 1.  Multivessel versus culprit-only revascularization: one time versus staged procedures for the ACS population.

Authors:  Pablo Codner; Ran Kornowski
Journal:  Curr Cardiol Rep       Date:  2012-08       Impact factor: 2.931

2.  Treatment of non-culprit lesions detected during primary PCI: long-term follow-up of a randomised clinical trial.

Authors:  A Ghani; J-H E Dambrink; A W J van 't Hof; J P Ottervanger; A T M Gosselink; J C A Hoorntje
Journal:  Neth Heart J       Date:  2012-09       Impact factor: 2.380

3.  Culprit-vessel percutaneous coronary intervention followed by contralateral angiography versus complete angiography in patients with ST-elevation myocardial infarction.

Authors:  Chadi Dib; Elias B Hanna; Muhammad A Chaudhry; Thomas A Hennebry; Stavros Stavrakis; Mazen S Abu-Fadel
Journal:  Tex Heart Inst J       Date:  2012

4.  Clinical impact of simultaneous complete revascularization vs. culprit only primary angioplasty in patients with st-elevation myocardial infarction and multivessel disease: a meta-analysis.

Authors:  Eliano Pio Navarese; Stefano De Servi; Antonino Buffon; Harry Suryapranata; Giuseppe De Luca
Journal:  J Thromb Thrombolysis       Date:  2011-02       Impact factor: 2.300

5.  Controversies in the treatment of patients with STEMI and multivessel disease: is it time for PCI of all lesions?

Authors:  Peter Ong; Udo Sechtem
Journal:  Clin Res Cardiol       Date:  2016-02-05       Impact factor: 5.460

6.  Complete versus incomplete coronary revascularization of patients with multivessel coronary artery disease.

Authors:  Yader Sandoval; Emmanouil S Brilakis; Mariana Canoniero; Demetris Yannopoulos; Santiago Garcia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-03

7.  Fine-tuning treatment for patients with ST-elevation myocardial infarction.

Authors:  Feng Qian; Edward L Hannan
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

Review 8.  Complete versus culprit-only revascularization in ST-elevation myocardial infarction and multivessel disease.

Authors:  Giuseppe Di Pasquale; Elisa Filippini; Pier Camillo Pavesi; Gianfranco Tortorici; Gianni Casella; Pietro Sangiorgio
Journal:  Intern Emerg Med       Date:  2016-03-07       Impact factor: 3.397

9.  How Should We Treat Multi-Vessel Disease in STEMI Patients?

Authors:  Victar Hsieh; Shamir R Mehta
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

10.  Initial culprit-only versus initial multivessel percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: results from the Ibaraki Cardiovascular Assessment Study registry.

Authors:  Daisuke Abe; Akira Sato; Tomoya Hoshi; Noriyuki Takeyasu; Masako Misaki; Mayu Hayashi; Kazutaka Aonuma
Journal:  Heart Vessels       Date:  2013-03-26       Impact factor: 2.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.